Phase II study to evaluate combining gemcitabine with flutamide in advanced pancreatic cancer patients

British Journal of Cancer

Volumn 87, Issue 7, 2002, Pages 716-719

  Corrie, Pippa ^a   Mayer, A ^a   Shaw, J ^a   D'ath S ^a   Blagden, S ^a   Blesing, C ^b   Price, P ^c   Warner, N ^b  

^a ADDENBROOKE S HOSPITAL   (United Kingdom)

^b CHURCHILL HOSPITAL   (United Kingdom)

^c HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

Flutamide; Gemcitabine; Pancreatic cancer

Indexed keywords

FLUTAMIDE; GEMCITABINE;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANEMIA; ANTINEOPLASTIC ACTIVITY; ARTICLE; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURVIVAL; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; DEEP VEIN THROMBOSIS; DIARRHEA; DRUG SAFETY; DRUG TOLERANCE; FATIGUE; FEMALE; FEVER; HOT FLUSH; HUMAN; INFECTION; JAUNDICE; LIVER TOXICITY; MALE; MASTALGIA; MUCOSA INFLAMMATION; NAUSEA; NEUTROPENIA; PANCREAS CANCER; PERIPHERAL NEUROPATHY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RASH; THROMBOCYTOPENIA;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; DEOXYCYTIDINE; FEMALE; FLUTAMIDE; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; PANCREATIC NEOPLASMS; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0037163734     PISSN: 00070920     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjc.6600523     Document Type: Article

References (11)

1. Burris HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, Cripps MC, Portenoy RK, Storniolo AM, Tarassoff P, Nelson R, Dorr FA, Stephens CD, von Hoff DD (1997) Improvements in survival and clinical benefit with Gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomised trial. J. Clin. Oncol 15: 2403-2413
2. Corbishley TP, Iqbal MJ, Wilkinson ML, Williams R (1986) Androgen receptor in human normal and malignant pancreatic tissue and cell lines. Cancer 57: 1992-1995
3. Gehan EA (1961) The determination of the number of patients required in a follow-up trial of a new chemotherapeutic agent. J. Chron. Dis 13: 346-353
4. Greenway BA (1998) Effect of flutamide on survival in patients with pancreatic cancer: results of a prospective, randomised, double-blind placebo controlled trial. Br. Med. J 316: 1935-1938
5. Greenway BA, Duke D, Pym B, Iqbal MJ, Johnson PJ, Williams R (1982) The control of human pancreatic adenocarcinoma xenografts in nude mice by hormone therapy. Br. J. Surg 69: 595-797
6. Greenway BA, Iqbal MJ, Johnson PJ, Williams R (1983) Low testosterone concentrations in patients with carcinoma of the pancreas. Br. Med. J 286: 93-95
7. Iqbal MJ, Greenway BA, Wilkinson ML, Johnson PJ, Williams R (1983) Sex steroid enzymes, aromatase and 5αreductase in the pancreas: a comparison of normal adult, foetal and malignant tissue. Clin. Sci 65: 71-75
8. Kelly DM, Benjamin IS (1995) Pancreatic carcinoma. Ann. Oncol 6: 19-28
9. Louvet C, Andre T, Lledo G, Hammel P, Bleiberg H, Bouleuc C, Gamelin E, Flesch M, Cvitkovic E, de Gramont A (2002) Gemcitabine combined with oxaliplatin in advanced pancreatic adenocarcinoma; final results oof the GERCOR multicenter phae Ii study. J. Clin. Oncol 20: 1512-1518
10. Neoptolemos JP, Dunn JA, Stocken DD, Almond J, Link K, Beger H, Bassi C, Falconi M, Pederzoli P, Dervenis C, Fernandez-Cruz L, Lacaine F, Pap A, Spooner D, Kerr DJ, Friess H, Buchler MW (2001) Adjuvant chemoradiotherapy and chemotherapy in resectable pancreatic cancer: a randomised controlled trial. Lancet 358: 1576-1585
11. Shaw J, Mayer A, Corrie P. (2000) Phase II study of flutamide in unresectable pancreatic cancer. Proc. Am. Soc. Clin. Oncol 19: 274a